Tapentadol IR: Phase III data

In a double-blind Phase III trial in 659 patients, tapentadol IR and oxycodone IR significantly improved SPID5-day vs. placebo (p<0.001). Also, both low and high doses of tapentadol IR (50 and 75 mg) ...